Arcturus reverse merges into the market, steering RNA projects to the clinic
Israel’s Alcobra started out 2017 with a disaster, forced to concede that their Phase III study of MDX — its only drug in the clinic — had flopped against a placebo. The news ruined its share price $ADHD and set in motion the search for a new future that ended with the news that it struck a reverse merger deal with the RNA biotech Arcturus.
Arcturus will now steer its way into the public market with a combined company that has $40 million in cash and some new options on raising more. The biotech also has a few partners, including Takeda (on NASH) and Ultragenyx, with plans to move into the clinic for the first time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
